文献速递姑息放疗与转移瘤中枢神经肿瘤放疗

脑转移患者颅外转移病灶评估:在生存预测模型演进背景下需要多少努力?

Assessment of extracranial metastatic disease in patients with brain metastases: How much effort is needed in the context of evolving survival prediction models?
PubMed 文献 · Radiother Oncol · 2021-03-04

该文讨论脑转移患者生存预测模型中颅外转移评估的相关问题。文章指出当前模型在组分、数量和权重上存在差异,部分组分易评估而另一些存在评估者间不一致风险。本文聚焦颅外转移及潜在替代标志物(如血液生物标志物),识别争议领域并为未来研究提供建议,以助构建更准确的预后模型。

要点

  • 生存预测模型可辅助临床决策,避免过度或不足治疗。
  • 模型组分评估难度不一,部分存在评估者间不一致风险。
  • 颅外转移评估及血液生物标志物是争议焦点与研究方向。

核心结论

  • 颅外转移评估在生存预测模型中存在争议,需未来研究优化以提高模型准确性。

主要发现

  • 当前生存预测模型在组分、总体数量和个体组分权重上存在差异。
  • 部分模型组分易于评估(如年龄、原发肿瘤类型),另一些则存在评估者间不一致和时间依赖变异的风险。
  • 本文识别了颅外转移评估及潜在替代标志物(如血液生物标志物)相关的争议领域。

临床怎么用

  • 临床医生可参考生存预测模型进行决策支持,但需注意颅外转移评估的不确定性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Survival prediction models may serve as decision-support tools for clinicians who have to assign the right treatment to each patient, in a manner whereby harmful over- or undertreatment is avoided as much as possible. Current models differ regarding their components, the overall number of components and the weighting of individual components. Some of the components are easy to assess, such as age or primary tumor type. Others carry the risk of inter-assessor inconsistency and time-dependent variation. The present publication focuses on issues related to assessment of extracranial metastases and potential surrogates, e.g. blood biomarkers. It identifies areas of controversy and provides recommendations for future research projects, which may contribute to prognostic models with improved accuracy.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Nieder C, Mehta MP, Guckenberger M, et al. Assessment of extracranial metastatic disease in patients with brain metastases: How much effort is needed in the context of evolving survival prediction models? Radiother Oncol. 2021. PMID: 33675870. doi:10.1016/j.radonc.2021.02.038

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。